Drugs / Recombinant novel coronavirus protein vaccine (CHO cells)
Recombinant novel coronavirus protein vaccine (CHO cells)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT05616754 Comparator | Nov 2022 → Jul 2023 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | No outcome recorded |
| — | NCT06025812 Comparator | Sep 2023 → May 2024 | Coronaviridae infectious disease | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | No outcome recorded |
| — | NCT05850507 Comparator | Mar → Oct 2023 | Coronaviridae infectious disease | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant novel coronavirus protein vaccine (CHO cells) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06025812 ↗ |
| Modality | Vaccine | “received the experimental vaccine and the control vaccine respectively” NCT05616754 ↗ |
| Route | Intramuscular | “Intramuscular injection of deltoid muscle of upper arm” NCT05850507 ↗ |